NEKTAR THERAPEUTICS (NKTR)

US6402681083 - Common Stock

1.33  +0.07 (+5.56%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

NEKTAR THERAPEUTICS

NASDAQ:NKTR (6/12/2024, 2:05:53 PM)

1.33

+0.07 (+5.56%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month168.94%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap244.21M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

NKTR Daily chart

Company Profile

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. The company is headquartered in San Francisco, California and currently employs 216 full-time employees. The firm is focused on discovering and developing medicines in the field of immunotherapy. The firm has a research and development pipeline of investigational medicines in oncology and immunology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its pipeline NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body’s innate and adaptive immunity. Its Rezpegaldesleukin (REZPEG) pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. REZPEG is being developed as a self-administered injection for a number of autoimmune and inflammatory diseases.

Company Info

NEKTAR THERAPEUTICS

455 Mission Bay Boulevard South

San Francisco CALIFORNIA 94158

P: 14154825300

CEO: Howard W. Robin

Employees: 216

Website: https://www.nektar.com/

NKTR News

News Image6 hours ago - Nektar TherapeuticsNektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of a poster highlighting new preclinical data on NKTR-0165 at the European...

News Image13 days ago - Nektar TherapeuticsNektar Management to Present at Upcoming Investor Conferences

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences: Jefferies Healthcare Conference in New...

News Imagea month ago - InvestorPlaceNKTR Stock Earnings: Nektar Therapeutics Meets EPS, Beats Revenue for Q1 2024

NKTR stock results show that Nektar Therapeutics met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

News Imagea month ago - BusinessInsiderNKTR Stock Earnings: Nektar Therapeutics Meets EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nektar Therapeutics (NASDAQ:NKTR) just reported results for the first quarter o...

News Imagea month ago - Nektar TherapeuticsNektar Therapeutics Reports First Quarter 2024 Financial Results

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2024. Cash and investments in...

News Imagea month ago - Nektar TherapeuticsNektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2024 on Thursday, May 9, 2024, after the close of...

NKTR Twits

Here you can normally see the latest stock twits on NKTR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example